CMV Recombinant Proteins 

Cytomegalovirus (CMV) is a member of the Herpesviridae family and is a significant pathogen in immunocompromised individuals, transplant recipients, and congenital infections. CMV proteins, such as immediate early antigens (IE1/IE2), tegument proteins (pp65), and envelope glycoproteins (gB, gH), play crucial roles in viral replication, immune evasion, and host-cell interaction.

Content of CMV Recombinant Protein

• Production:
  • Produced using bacterial (E. coli), yeast, insect, or mammalian cell systems to ensure proper folding and biological activity.
  • Purified using techniques such as affinity chromatography (e.g., His-tag, GST-tag) or ion-exchange chromatography.
• Variants:
  • Structural proteins (e.g., pp65, gB) for studying viral assembly and immune response.
  • Regulatory proteins (e.g., IE1, IE2) for examining viral transcription and immune evasion.
  • Synthetic peptides derived from immunodominant regions for diagnostic and immunological applications.
• Specifications:
  • Purity: >90% as assessed by SDS-PAGE and HPLC.
  • Activity: Validated through functional assays such as ELISA, Western blotting, or cell-based assays.
  • Stability: Supplied in optimized buffer systems for long-term storage at -80°C.

Applications of CMV Recombinant Protein

• Serological Diagnostics:
  • CMV recombinant proteins, such as pp65 and gB, are used in ELISA and Western blot assays to detect CMV-specific antibodies in clinical samples.
  • Serve as standards or controls in diagnostic test development.
• Vaccine Development:
  • Recombinant CMV glycoproteins (e.g., gB, gH) are critical antigens for developing subunit vaccines targeting CMV infections.
  • Used in preclinical studies to evaluate immunogenicity and protective efficacy.
• Pathogenesis Research:
  • Study the role of CMV proteins in immune evasion, such as modulation of MHC class I expression by IE proteins.
  • Investigate viral protein interactions with host cell machinery to understand replication and latency mechanisms.

CMV recombinant proteins are indispensable for advancing CMV research and combating its clinical impact. Their applications in diagnostics, vaccine development, and therapeutic studies make them invaluable tools in virology and immunology. Their versatility ensures significant contributions to understanding CMV pathogenesis and developing effective interventions.